Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
78.88
-3.63 (-4.40%)
Jun 16, 2026, 4:00 PM EDT - Market closed
Dianthus Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 627.67 | 51.09 | 22.79 | 132.33 | 15.37 | 131.65 |
Short-Term Investments | 483.59 | 353.21 | 252.45 | 41.39 | 60.13 | 45.28 |
Cash & Short-Term Investments | 1,111 | 404.3 | 275.24 | 173.72 | 75.49 | 176.93 |
Cash Growth | 322.16% | 46.89% | 58.44% | 130.12% | -57.33% | 18.87% |
Accounts Receivable | 1.23 | 0.05 | - | - | - | - |
Other Receivables | - | - | 0.81 | 0.48 | 5.64 | - |
Total Trade Receivables | 1.23 | 0.05 | 0.81 | 0.48 | 5.64 | - |
Other Current Assets | 7.42 | 5.09 | 4.86 | 3.26 | 0.91 | 3.77 |
Total Current Assets | 1,120 | 409.44 | 280.9 | 177.45 | 82.03 | 180.69 |
Net Property, Plant & Equipment | 1.57 | 1.63 | 1.75 | 0.8 | 0.96 | 7.46 |
Long-Term Investments | 113.87 | 110.14 | 81.73 | - | - | - |
Other Long-Term Assets | 11.54 | 9.72 | 9.63 | 1.15 | 0.12 | 1.78 |
Total Assets | 1,247 | 530.92 | 374.01 | 179.41 | 83.11 | 189.93 |
Accounts Payable | 5.27 | 9.73 | 4.58 | 2.61 | 1.17 | 3.04 |
Accrued Expenses | 31.13 | 19.45 | 13.07 | 6.5 | 6.61 | 7.82 |
Current Portion of Leases | 0.4 | 0.37 | 0.32 | 0.42 | 0.35 | - |
Unearned Revenue | 1.49 | 1.19 | 0.48 | 0.1 | 0.1 | - |
Total Current Liabilities | 38.28 | 30.73 | 18.45 | 9.63 | 8.23 | 10.86 |
Long-Term Leases | 0.97 | 1.02 | 1.17 | 0.17 | 0.44 | - |
Other Long-Term Liabilities | 6.32 | 5.77 | 1.91 | 0.74 | 0.79 | 6.4 |
Total Long-Term Liabilities | 7.29 | 6.79 | 3.08 | 0.9 | 1.23 | 6.4 |
Total Liabilities | 45.57 | 37.52 | 21.53 | 10.54 | 9.45 | 17.26 |
Common Stock | 0.05 | 0.04 | 0.03 | 0.02 | - | 0.06 |
Additional Paid-in Capital | 1,579 | 829.6 | 526.73 | 258.23 | 1.66 | 498.21 |
Accumulated Other Comprehensive Income | -0.58 | 0.49 | 0.11 | 0.05 | -0.16 | -0.03 |
Retained Earnings | -377.56 | -336.73 | -174.39 | -89.42 | -45.87 | -325.57 |
Total Common Shareholders' Equity | 1,201 | 493.4 | 352.48 | 168.87 | -44.37 | 172.67 |
Minority Interest | - | - | - | - | 118.02 | - |
Shareholders' Equity | 1,201 | 493.4 | 352.48 | 168.87 | 73.66 | 172.67 |
Total Liabilities & Equity | 1,247 | 530.92 | 374.01 | 179.41 | 83.11 | 189.93 |
Total Debt | 1.36 | 1.39 | 1.49 | 0.59 | 0.79 | 0 |
Net Cash (Debt) | 1,110 | 402.91 | 273.75 | 173.13 | 74.7 | 176.93 |
Net Cash Growth | 175.47% | 47.18% | 58.12% | 131.76% | -57.78% | 18.87% |
Net Cash Per Share | 26.64 | 10.43 | 8.22 | 33.60 | 85.45 | 202.56 |
Book Value | 1,201 | 493.4 | 352.48 | 168.87 | -44.37 | 172.67 |
Book Value Per Share | 28.84 | 12.78 | 10.58 | 32.77 | -50.75 | 197.69 |
Tangible Book Value | 1,201 | 493.4 | 352.48 | 168.87 | -44.37 | 172.67 |
Tangible Book Value Per Share | 28.84 | 12.78 | 10.58 | 32.77 | -50.75 | 197.69 |